00
002630.KO ORIENTBIO Inc.
- Market cap
- KRW 35.4B
- P/E
- -
- P/B
- 0.48x
- ROE
- 26.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 002630.KO undervalued?
Graham numberThe Graham number of ORIENTBIO Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ORIENTBIO Inc. fundamental analysis
No fundamental analysis for ORIENTBIO Inc. yet.
ORIENTBIO Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ORIENTBIO Inc.
ORIENT BIO Inc. operates in the bio-industry in South Korea and internationally. It engages in the production, export, import, and life science-related research and development of laboratory animals; and offers various equipment for research environment. The company also provides infrastructural solution; health checking; generic testing; molecular biological generic testing; generic transformation; phenotyping; preconditioning; surgical treatment; transgenic services; eggs …
Full company profileORIENTBIO Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ORIENTBIO Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 109B | 121B | 30.4B | 37.7B | 52.0B | 26.3B | 28.8B | 28.0B | 29.4B | 29.8B | 26.4B |
| Gross Profit | 8.37B | 14.9B | 3.01B | 7.20B | 19.2B | 9.01B | 9.82B | 9.58B | 7.20B | 5.18B | 8.15B |
| Operating Income | -9.29B | -6.56B | -9.23B | -11.2B | 2.31B | -3.78B | 3.47B | 4.45B | -3.08B | -4.13B | 21.6B |
| EBITDA | - | -3.81B | -1.66B | -6.95B | -10.1B | 997M | -9.25B | 15.6B | -11.0B | -2.23B | 22.0B |
| Net Income | -19.1B | -13.9B | -19.5B | -10.9B | -15.3B | 34.2B | -12.4B | 12.9B | -13.2B | -4.57B | 19.4B |
| EPS | -257 | -184 | -192 | -107 | -129 | 288 | -210 | 217 | -223 | -77 | 327 |
| Balance Sheet | |||||||||||
| Total Assets | 173B | 190B | 84.1B | 72.1B | 71.5B | 105B | 81.1B | 97.0B | 84.8B | 81.6B | 83.4B |
| Total Liabilities | 74.7B | 110B | 21.4B | 20.1B | 23.0B | 21.8B | 9.66B | 11.9B | 12.9B | 13.1B | 11.2B |
| Shareholders' Equity | 70.3B | 52.7B | 64.8B | 52.0B | 48.5B | 83.2B | 71.4B | 85.1B | 71.8B | 68.5B | 72.3B |
| Cash & Short-term Investments | 21.0B | 37.1B | 10.1B | 3.15B | 11.7B | 59.0B | 5.93B | 6.11B | 6.53B | 5.83B | 11.0B |
| Total Debt | 51.7B | 64.1B | 8.25B | 7.22B | 8.11B | 7.40B | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.11B | -1.97B | -11.5B | -3.90B | 8.74B | 2.35B | 1.16B | 3.76B | 752M | 2.60B | 16.0B |
| Capital Expenditure | 5.28B | 2.99B | 16.1B | 743M | 256M | 2.21B | 486M | 925M | 4.79B | 2.05B | 380M |
| Free Cash Flow | - | -5.56B | -30.0B | -6.55B | 8.48B | 141M | 674M | 2.83B | -4.04B | 546M | 15.6B |
| Ratios | |||||||||||
| ROE | -27.2% | -26.3% | -30.1% | -20.9% | -31.5% | 41.1% | -17.4% | 15.1% | -18.4% | -6.7% | 26.8% |
| ROA | -11.1% | -7.3% | -23.2% | -15.1% | -21.4% | 32.6% | -15.3% | 13.3% | -15.6% | -5.6% | 23.2% |
| Net Profit Margin | -17.5% | -11.4% | -64.2% | -28.9% | -29.4% | 130.1% | -43.1% | 46.0% | -44.9% | -15.3% | 73.5% |
| Debt to Equity | 0.74x | 1.22x | 0.13x | 0.14x | 0.17x | 0.09x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ORIENTBIO Inc. dividends
ORIENTBIO Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 0.5:1 on Sep 22, 2026.
Who owns ORIENTBIO Inc.
- Insiders 40.20%
- Institutions 0.00%
- Public & others 59.80%
- Shares outstanding 29.6M
- Free float 22.5M
ORIENTBIO Inc. company profile
- Company name
- ORIENTBIO Inc.
- Ticker
- 002630.KO
- ISIN
- KR7002630002
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Fiscal year end
- March
- Address
- 322, Galmachi-ro, Seongnam-si, South Korea
- Phone
- 82 31 730 6000
- Website
- orient.co.kr
About ORIENTBIO Inc.
ORIENT BIO Inc. operates in the bio-industry in South Korea and internationally. It engages in the production, export, import, and life science-related research and development of laboratory animals; and offers various equipment for research environment. The company also provides infrastructural solution; health checking; generic testing; molecular biological generic testing; generic transformation; phenotyping; preconditioning; surgical treatment; transgenic services; eggs and avian research; support services for husbandry tasks; diagnostic and kits; claim management; serology regents; supply of biological materials used for new drug development process; and mouse, rat, and hamster antibody production testing services. In addition, it engages in automotive and automobile parts production and sales; preclinical and clinical trial agency business; manufacturing, import, and export pharmaceuticals, manufacturing, processing, wholesaling, and retailing of watches; and construction works. It has strategic partnerships with ELLEGARD in the Netherlands and CSIMC in China. It serves research institutions, pharmaceutical companies, and healthcare providers. The company was formerly known as Orient Co., Ltd. and changed its name to ORIENT BIO Inc. in 2005. ORIENT BIO Inc. was founded in 1959 and is headquartered in Seongnam-si, South Korea.
ORIENTBIO Inc. management
2- Mr. Jae-Jin ChangChairperson, President & CEO · born 1961
- Mr. Tae-Seok HanManaging Director of Sales · born 1977